|Mr. Jeffrey Alan Wolf||Founder, Chairman, CEO & Pres||834.3k||N/A||1963|
|Dr. Jeff T. Hutchins||Chief Scientific Officer & COO||536k||N/A||1959|
|Mr. Robert J. Jakobs||VP of Fin., Sec. & Controller||N/A||N/A||1955|
|Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.||Chief Medical Advisor and Member of Scientific & Clinical Advisory Board||N/A||N/A||N/A|
|Colonel George E. Peoples Jr., M.D., FACS||Chief Medical Advisor||N/A||N/A||N/A|
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.
Heat Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.